BACKGROUND: Obsessive-compulsive disorder (OCD) is a chronic condition that often produces lifelong morbidity, but few studies have examined long-term outcome (greater than 5 years) in adult patients. Available studies suggest that 32-74% of adult OCD patients will experience clinical improvement over the long term. However, these studies were conducted before validated OCD rating scales were established and the development of evidence-based treatments for OCD. METHODS: We investigated the 10-20 year outcome of 83 of 165 eligible subjects previously enrolled after participation in placebo-controlled trials of serotonin reuptake inhibitor (SRI) medications for OCD. We examined the association between clinical characteristics at initial assessment and OCD symptom severity at follow-up. We hypothesized that primary OCD symptom dimension and initial response to pharmacotherapy with serotonin reuptake inhibitors would be associated with later symptom severity. RESULTS: Only 20% (17 of 83) of subjects had experienced a remission of their OCD symptoms at follow-up (Y-BOCS ≤ 8). Forty-nine percent (41 of 83) of subjects were still experiencing clinically significant OCD symptoms. Response to initial SRI pharmacotherapy was significantly associated with long-term outcome: 31% (13 of 42) of subjects who responded (CGI < 3) to initial SRI pharmacotherapy were remitted at follow-up, compared to 12% (3 of 25) of partial responders and none of the 16 subjects who had no response to initial SRI pharmacotherapy. We did not find a significant association between long-term clinical outcome and any of the OCD symptom dimensions. CONCLUSION: Despite the introduction and dissemination of several evidence-based treatments for OCD, most adult OCD patients do not achieve remission. Initial response to pharmacotherapy was strongly associated with long-term outcome.
BACKGROUND:Obsessive-compulsive disorder (OCD) is a chronic condition that often produces lifelong morbidity, but few studies have examined long-term outcome (greater than 5 years) in adult patients. Available studies suggest that 32-74% of adult OCDpatients will experience clinical improvement over the long term. However, these studies were conducted before validated OCD rating scales were established and the development of evidence-based treatments for OCD. METHODS: We investigated the 10-20 year outcome of 83 of 165 eligible subjects previously enrolled after participation in placebo-controlled trials of serotonin reuptake inhibitor (SRI) medications for OCD. We examined the association between clinical characteristics at initial assessment and OCD symptom severity at follow-up. We hypothesized that primary OCD symptom dimension and initial response to pharmacotherapy with serotonin reuptake inhibitors would be associated with later symptom severity. RESULTS: Only 20% (17 of 83) of subjects had experienced a remission of their OCD symptoms at follow-up (Y-BOCS ≤ 8). Forty-nine percent (41 of 83) of subjects were still experiencing clinically significant OCD symptoms. Response to initial SRI pharmacotherapy was significantly associated with long-term outcome: 31% (13 of 42) of subjects who responded (CGI < 3) to initial SRI pharmacotherapy were remitted at follow-up, compared to 12% (3 of 25) of partial responders and none of the 16 subjects who had no response to initial SRI pharmacotherapy. We did not find a significant association between long-term clinical outcome and any of the OCD symptom dimensions. CONCLUSION: Despite the introduction and dissemination of several evidence-based treatments for OCD, most adult OCDpatients do not achieve remission. Initial response to pharmacotherapy was strongly associated with long-term outcome.
Authors: Daniel L Lafleur; Christopher Pittenger; Ben Kelmendi; Tom Gardner; Suzanne Wasylink; Robert T Malison; Gerard Sanacora; John H Krystal; Vladimir Coric Journal: Psychopharmacology (Berl) Date: 2005-12-22 Impact factor: 4.530
Authors: Diane E Dickel; Jeremy Veenstra-VanderWeele; Nancy J Cox; Xiaolin Wu; Daniel J Fischer; Michelle Van Etten-Lee; Joseph A Himle; Bennett L Leventhal; Edwin H Cook; Gregory L Hanna Journal: Arch Gen Psychiatry Date: 2006-07
Authors: S Evelyn Stewart; Jesen A Fagerness; Jill Platko; Jordan W Smoller; Jeremiah M Scharf; Cornelia Illmann; Eric Jenike; Nadia Chabane; Marion Leboyer; Richard Delorme; Michael A Jenike; David L Pauls Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2007-12-05 Impact factor: 3.568
Authors: Michael H Bloch; Angeli Landeros-Weisenberger; Maria C Rosario; Christopher Pittenger; James F Leckman Journal: Am J Psychiatry Date: 2008-10-15 Impact factor: 18.112
Authors: Elizabeth Shephard; Marcelo C Batistuzzo; Marcelo Q Hoexter; Emily R Stern; Pedro F Zuccolo; Carolina Y Ogawa; Renata M Silva; Andre R Brunoni; Daniel L Costa; Victoria Doretto; Leonardo Saraiva; Carolina Cappi; Roseli G Shavitt; H Blair Simpson; Odile A van den Heuvel; Euripedes C Miguel Journal: Braz J Psychiatry Date: 2022 Mar-Abr
Authors: Elizabeth Shephard; Emily R Stern; Odile A van den Heuvel; Daniel L C Costa; Marcelo C Batistuzzo; Priscilla B G Godoy; Antonio C Lopes; Andre R Brunoni; Marcelo Q Hoexter; Roseli G Shavitt; Y C Janardhan Reddy; Christine Lochner; Dan J Stein; H Blair Simpson; Euripedes C Miguel Journal: Mol Psychiatry Date: 2021-01-07 Impact factor: 15.992
Authors: Boris van Passel; Unna Danner; Alexandra Dingemans; Eric van Furth; Lot Sternheim; Annemarie van Elburg; Agnes van Minnen; Marcel van den Hout; Gert-Jan Hendriks; Daniëlle Cath Journal: BMC Psychiatry Date: 2016-11-10 Impact factor: 3.630